I've been thinking a lot about longevity lately… not the peptide-injecting, supplement-stacking version, but what it looks like when it reaches the rest of us. The first wave of companies (@prenuvo, @function, @GrailBio) did something important: they proved consumers will pay for preventive care. But that customer is still largely a highly activated early adopter. McKinsey puts that group at just 25% of the market. The other 75% want to age well too, they're just not building a parallel health system outside their doctor to do it. I think that the next wave of longevity won't win by going deeper on biohackers, but by solving for adherence over diagnosis, earning provider trust instead of bypassing it, and treating brand as infrastructure in a category where consumers are being asked to hand over their most personal data. More here: maveronvc.substack.com/p/lon…

1/ At @Maveron, we're looking to invest in a returns retailer that builds its own brand — one that attracts & retains customers w/o relying on the independent brands it carries. Read more on our POV below 👇🏾

1/ @jstoffer and I are excited to share the final installment of our AI Unleashed series, covering @Maveron’s Power Redistribution focus area!